Clinical Trial Update: A Study to Assess S011806 (DC-806 or LY4100504) in Healthy Adult Participants and Participants With Chronic Plaque Psoriasis [Phase 1]

View source ↗

Summary

This update notes the completion of a Phase 1 study of S011806 (DC-806 or LY4100504) in healthy adults and participants with chronic plaque psoriasis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• S011806 (DC-806 or LY4100504) (DC-806 / LY4100504)

Snippet

Sponsor: DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company | Conditions: Plaque Psoriasis | Phase 1 | Status: COMPLETED